ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print April 22, 2009, 10.1183/09031936.00089407
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/3/721    most recent
09031936.00089407v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stamatiou, R.
Right arrow Articles by Hatziefthimiou, A. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stamatiou, R.
Right arrow Articles by Hatziefthimiou, A. A.
Eur Respir J 2009; 34:721-730
Copyright ©ERS Journals Ltd 2009

Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells

R. Stamatiou1, E. Paraskeva1, K. Boukas2, K. I. Gourgoulianis3, P-A. Molyvdas1 and A. A. Hatziefthimiou1

Depts of 1 Physiology, 2 Immunology and Histocompatibility, and 3 Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.

CORRESPONDENCE: A. A. Hatziefthimiou, Dept of Physiology, Medical School, University of Thessaly, P.O. Box 1400, Mezourlo 41110, Larissa, Greece. E-mail: axatzi{at}med.uth.gr

Keywords: Airway smooth muscle cells, autophagy, azithromycin, proliferation

Received: July 16, 2007
Accepted April 3, 2009

Azithromycin is used in long-term, low-dose treatment of airway diseases where airway wall remodelling is present. Since it improves total score symptom and respiratory function of such patients, we hypothesise that azithromycin's additional clinical benefits are due to an inhibition of airway smooth muscle cell (SMC) proliferation.

Rabbit tracheal SMCs were treated with azithromycin (10–5 to 10–6 M) in the presence or absence of 10% fetal bovine serum (FBS). The proliferation was estimated using the Cell Titer 96® AQueous One Solution Assay (Promega, Madison, WI, USA). Cell viability was assessed with Trypan blue staining and flow cytometry after 7-aminoactinomycin D (7-AAD) staining. Induction of autophagy was studied by indirect immmunofluorescence and/or Western blotting with antibodies against human smooth muscle {alpha}-actin, beclin 1, light chain 3 and caspase 3. The involvement of the phosphoinositide 3-kinase pathway was investigated with the inhibitors LY294002 and wortmannin.

Incubation with azithromycin for 72 h in the presence of FBS reduced SMC proliferation and viability in a dose-dependent manner. Azithromycin treatment was accompanied by the formation of cytoplasmic vacuoles, characteristic of autophagy. All these effects were reversible after azithromycin removal and prevented by the autophagy inhibitor, 3-methyladenine, or LY294002, but not by wortmannin.

In conclusion, azithromycin reduces proliferation and causes autophagy of airway SMCs.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the European Respiratory Society.